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PTEN is a candidate tumour suppressor gene and frequently mutated in multiple cancers, however, not in pancreatic cancer.
Recently, it has been demonstrated that PTEN expression is regulated by TGF-b1. Using TGF-b1 transgenic mice (n=7) and
wildtype littermates (n=6), as well as pancreatic tissues obtained from organ donors (n=10) and patients with pancreatic
cancer (n=10), we assessed the expression of PTEN by means of immunohistochemistry and semiquantitative PCR analysis. In
addition, PANC-1 cells were treated with TGF-b1 in vitro and the levels of PTEN mRNA were determined in these cells. In
human pancreatic cancers PTEN mRNA levels were signiﬁcantly decreased (P50.05). In addition, in the pancreas of TGF-b1
transgenic mice the expression of PTEN was signiﬁcantly reduced (P50.01), as compared to wildtype littermates and
incubation of PANC-1 cells with TGF-b1 decreased PTEN mRNA levels after 24 h. Inasmuch as TGF-b1 decreases PTEN
expression in human pancreatic cancer cells and human pancreatic cancers overexpress TGF-b1, the reduced expression of
PTEN in pancreatic cancer may be mediated by TGF-b1 overexpression. Thus, although PTEN is not mutated in pancreatic
cancers, the reduction of its expression may give pancreatic cancer cells an additional growth advantage.
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Pancreatic cancer is an aggressive cancer with an increasing inci-
dence and poor survival (Warshaw and Fernandez-del Castillo,
1992; Hahn and Schmiegel, 1998). Less than 5% of patients with
pancreatic adenocarcinoma survive more than 5 years. The reason
for this poor survival is, among others, the presence of advanced
stages, the poor therapeutic options and the current incomplete
knowledge concerning the pathogenesis and biology of the tumour
(Warshaw and Fernandez-del Castillo, 1992; Hahn and Schmiegel,
1998). Recently, the molecular biology and the pathogenesis of
this cancer has been studied extensively, leading to the identiﬁca-
tion of K-ras mutations or the frequent inactivation of tumour
suppressor genes, such as p53, p16 or Smad4 (Warshaw and
Fernandez-del Castillo, 1992; Hahn and Schmiegel, 1998).
However, the exact molecular mechanisms of its pathogenesis
remain largely unknown. We and others have reported the
frequent overexpression of oncogenes and growth factors, such
as EGF, FGF, VEGF and PDGF in pancreatic cancers along with
the overexpression of their respective receptors (Korc et al,
1992; Ebert et al, 1995; Kornmann et al, 1997; Fujimoto et al,
1998). Furthermore, growth factors of the TGF-b superfamily
are also overexpressed in this tumour and TGF-b1 overexpression
is associated with poor survival in these patients (Friess et al,
1993). Although, TGF-b1 exerts an inhibitory effect on cancer cell
growth in vitro, it also stimulates the synthesis of the extracellular
matrix and has been implicated in the regulation of cell differen-
tiation, angiogenesis, immunosuppression and ﬁbrosis (Massague ￿,
1996; Korc, 1998; Lo ¨hr et al, 2001).
Recently, PTEN, a tumour suppressor gene which is located
on chromosome 10q23, was identiﬁed by positional cloning
(Steck et al, 1997; Li et al, 1997b). Several groups have reported
loss of heterozygosity, mutation or deletion of the gene in differ-
ent cancers, including glioblastoma, prostate, lung and breast
carcinoma and altered expression of PTEN was also detected
in various precancerous lesions (Steck et al, 1997; Li et al,
1997b; McMenamin et al, 1999; Perren et al, 1999; Sano et al,
1999; Mutter et al, 2000). PTEN has homology to a protein
tyrosine phosphatase and has the activity of a dual-speciﬁcity
phosphatase (Myers et al, 1997). In addition, recent studies indi-
cate that PTEN may function as a mediator of the
phosphatidylinositol (PI3') kinase pathway (Maehama and Dixon,
1998). These ﬁndings, along with the description of germline
mutations and deletions of PTEN in two hereditary cancer
predisposition diseases (Liaw et al, 1997; Marsh et al, 1997;
Nelen et al, 1997), i.e. Cowden Disease and the Bannayan-Zona-
na-syndrome, point to a role of PTEN as a tumour suppressor
gene in the pathogenesis of malignant tumours. However, PTEN
mutations or deletions do not seem to be present in pancreatic
cancer (Sakurada et al, 1997; Okami et al, 1998). Since PTEN
expression is regulated by TGF-b1 (Li et al, 1997a), we assessed
PTEN mRNA levels in human pancreatic cancers by RT–PCR
analysis and immunohistochemistry. In addition, we determined
the mRNA levels of PTEN in a model of TGF-b1 overexpressing
transgenic mice which develop pancreatic ﬁbrosis and studied the
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MATERIALS AND METHODS
The following products were purchased: Taq polymerase from
Gibco-BRL (Eggenstein, Germany). Oligonucleotides were
purchased from MWG-Biotech. (Ebersberg, Germany). All other
chemicals and reagents were of molecular biology grade and were
purchased from Sigma Chemical (Deisenhofen, Germany).
Transgenic mice
Transforming growth factor beta-1 overexpressing transgenic
mice were generated by the introduction of the rat insulin II
gene promotor fused to the murine TGF-b1 cDNA. The fusion
fragment was inserted in the EcoRI site of pBS containing the
human growth hormone (Sanvito et al, 1995). Seven transgenic
animals were used for this study; control animals were of the
BL6 strain. Transgenesis was determined on tail DNA by dot
blot or Southern hybridization. All animals were maintained on
laboratory chow and tap water. Animals were housed and treated
in accordance with appropriate guidelines. After 3–9 months
animals were sacriﬁced, the pancreas was removed and tissues
were snap frozen in liquid nitrogen. In all transgenic mice the
pancreas exhibited massive ﬁbrosis, as previously described
(Sanvito et al, 1995).
Tissue samples
Pancreatic cancer tissues (six female, four male) were obtained
from patients undergoing pancreatic surgery. Normal pancreatic
tissues were obtained from 10 individuals (ﬁve female) through
an organ donor programme. The median age of the patients with
pancreatic cancer was 61.5 years (range, 48–73 years). The median
age of the organ donors was 42 years (range, 37–47 years). Imme-
diately following surgical removal, all tissue samples were either
ﬁxed in Bouin’s solution or frozen in liquid nitrogen. All cancer
tissue samples were graded independently by a pathologist, and
classiﬁed histologically as adenocarcinoma of the exocrine
pancreas. This study was approved by the Ethics Committee of
the University of Berne, Switzerland.
Cell line
PANC-1 cells were cultured in DMEM medium (Gibco-BRL,
Gaithersburg, MA, USA) supplemented with 10% foetal calf serum
(FCS, Gibco-BRL), penicillin (100 U ml
71), and streptomycin
(100 U ml
71)a t3 7 8Ci n5 %C O 2 atmosphere. To analyze the
effect of TGF-b1 on cell morphology pancreatic cancer cell lines
were grown to 70% conﬂuence in DMEM containing 10% FCS.
Afterwards, cells were washed twice in serum free medium, starved
for 24 h in serum free medium and ﬁnally treated for 12 and 24 h
with 10 ng ml
71 TGF-b1 (R&D, Wiesbaden, Germany) or medium
alone (Geng et al, 1999). Thereafter total RNA was extracted using
the RNAclean kit (AGS, Heidelberg, Germany) as indicated by the
manufacturer.
RNA extraction
Total RNA was extracted from the human pancreatic tissues and
the pancreas of the transgenic mice by the acid guanidinium-thio-
cyanate method, as previously described (Ebert et al, 1994).
Polymerase chain reaction
Oligonucleotide primers were purchased from MWG-Biotech.
(Ebersberg, Germany). cDNAs were synthesized from total RNA
(1 mg sample
71) isolated from human and mouse pancreatic
tissues and the cancer cell line, using oligodeoxythymidylate and
reverse transcriptase. Following inactivation, 1 ml of the reaction
mixture were incubated in buffer containing 0.2 mM concentra-
tions of dATP, dCTP, dGTP, dTTP, 0.2 mM concentrations each
of oligonucleotide primers, 3 mM MgCl2 and a 106 buffer
consisting of 200 mM Tris-HCl (pH 8.0), 500 mM KCl, and 1 U
Taq polymerase. PCR primers were designed to amplify a region
spanning from 117 to 741 of the PTEN gene (F1, 5'-CAGAAA-
GACTTGAAGGCGTAT-3' and B1, 5'-AACGGCTGAGG-
GAACTC-3'), as previously described (Sano et al, 1999). The
624 bp fragment contains a NsiI restriction site allowing to distin-
guish it from the PTEN pseudogene (Sano et al, 1999). The
primers designed to amplify enolase comprise a region from 77
to 532 bp of the coding region of the enolase gene (E1, 5'-
TGGCAGGACTTCAGA-3'; E2, 5'-AGTGGCTAGAAGTTCACC-
3'). For semiquantitative analysis of PTEN mRNA levels in the
pancreas of transgenic and wildtype mice, the primer F1 was used
in conjunction with a different antisense primer (H1, 5'-
TCTAGGGCCTCTTGTGCCTTT-3') for the ampliﬁcation of a
622 bp fragment of mouse PTEN (Sano et al, 1999). Again, diges-
tion with NsiI allowed differentiation from the PTEN pseudogene
(Sano et al, 1999). In addition, primers speciﬁc for rat glyceralde-
hyde-3-phosphate dehydrogenase (GAP) mRNA (G1,G2) were also
added to the reaction in order to assess the PTEN mRNA levels in
the murine pancreas semiquantitatively. Primers were chosen as
previously reported (Ebert et al, 1999): G1, 5'-GCTGGATCCTT-
CATTGACCTCAACTAG-3'; G2, 5'-CGAGAATTCATACCAGGA-
AATGAGC-3'. PCR ampliﬁcation was performed after an initial
denaturation of 3 min at 948C, followed by 40 cycles of 45 s at
948C, 45 s at 548C and 1 min at 728C, and ﬁnally 10 min of ﬁnal
elongation at 728C. The PCR products were treated with NsiIa t
378C for 2 h and then separated on 1.5% agarose gel (Ebert et
al, 1994). The level of PTEN mRNA was analyzed densitometri-
cally from the agarose gel and was standardized to the
respective enolase or GAP mRNA level. The PTEN:enolase or
PTEN:GAP ratio was calculated and was analyzed by the t-test
(Siegel, 1956).
Immunohistochemistry
The presence of human PTEN was assessed using parafﬁn-
embedded tissue sections obtained from 10 patients with
pancreatic cancer undergoing pancreatic surgery. The human
tissues were ﬁxed in Bouin’s solution and parafﬁn embedded.
The anti-PTEN antibody (n-19) is an afﬁnity-puriﬁed goat poly-
clonal antibody raised against a peptide mapping at the amino-
terminus of human PTEN and was used at a dilution of 1:800
(Santa Cruz, CA, USA) (Steck et al, 1997; Sano et al, 1999).
In addition, sections were also incubated with the anti-PTEN
antibody C-20, which is a goat polyclonal antibody raised against
a peptide mapping at the carboxy-terminus of human PTEN
(Santa Cruz, CA, USA). Parafﬁn sections (4 mm thick) were
deparafﬁnized and rehydrated. For negative controls, the primary
antibodies were omitted and/or preimmune serum was used.
Furthermore, the anti-PTEN antibody n-19 was also incubated
with its respective blocking peptide which resulted in no speciﬁc
immunoreactivity in the immunohistochemical analysis, demon-
strating the speciﬁcity of the anti-PTEN antibody (Figure 1).
Endogenous peroxidase activity was inhibited by immersing the
sections in 0.3% H2O2 for 30 min. The sections were incubated
with the antiserum at 378C for 1 h and washed with PBS buffer.
The reaction was detected using the standard streptavidin-perox-
idase technique (LSAB kit, DAKO Hamburg, Germany). The
analysis was performed according to the manufacturer’s recom-
mendations and all reactions were performed at 238C. Finally,
the sections were counterstained with Mayer’s hematoxylin (Ebert
et al, 1994).
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The t-test was used to determine statistical difference. A P value of
less than 0.05 was considered statistically signiﬁcant (Siegel, 1956).
RESULTS
In human pancreatic cancers RT–PCR analysis revealed the
presence of PTEN mRNA in all samples (Figure 2A). PTEN
immunoreactivity was also detected in some of the cancer cells
(Figure 1A), whereas some cancer cells were devoid of PTEN
immunoreactivity. Immunohistochemical analysis of pancreatic
cancer tissue sections after incubation of the primary antibody
with the blocking peptide exhibited no speciﬁc immunoreactivity
(Figure 1B).
In order to determine the levels of PTEN mRNA in the pancreas
of individuals without pancreatic disease and in the pancreas of
patients with pancreatic adenocarcinoma we coampliﬁed cDNA
fragments encoding PTEN mRNA and enolase mRNA. In compar-
ison with the PTEN mRNA levels in the normal pancreas obtained
from organ donors without malignant disease of the pancreas, we
found a signiﬁcant reduction of PTEN mRNA levels in the cancer
tissues (P50.01) (Figure 2A,C).
Since PTEN expression is regulated in part by TGF-b1 which is
overexpressed in pancreatic cancer cells, we studied the levels of
PTEN mRNA in the pancreas of transgenic mice overexpressing
TGF-b1. These mice exhibit massive ﬁbrosis of the exocrine
pancreas through overexpression of TGF-b1 under the control of
a rat insulin II gene promotor. Using semiquantitative RT–PCR,
we determined the PTEN mRNA levels in the pancreas of seven
transgenic and six wildtype mice (Figure 2B). All mice expressed
PTEN mRNA and GAP mRNA in the pancreas, as determined
by RT–PCR analysis of cDNAs generated from total RNA. After
quantiﬁcation of PTEN mRNA levels using semiquantitative RT–
PCR we detected a signiﬁcant reduction of PTEN mRNA levels
in the pancreas of the TGF-b1 overexpressing mice as compared
to the normal pancreas (P50.05) (Figure 2B,C).
Finally, in order to demonstrate a direct effect of TGF-b1o n
PTEN mRNA levels in pancreatic cancer cells in vitro, we incubated
PANC-1 cancer cells with TGF-b1 (10 ng ml
71) for 12 and 24 h.
Semiquantitative RT–PCR analysis was performed via coampliﬁca-
tion of PTEN and enolase mRNA. PANC-1 cells expressed
abundant PTEN mRNA (Figure 2D). Using this semiquantitative
RT–PCR analysis we observed no reduction of PTEN mRNA levels
after 12 h of TGF-b1 treatment (+) as compared to the untreated
control (7). However, after 24 h incubation with TGF-b1 a more
than 60% reduction of PTEN mRNA levels was observed in PANC-
1 cancer cells (Figure 2D, left).
DISCUSSION
The tumour suppressor gene PTEN, located on chromosome
10q23, encodes a protein tyrosine phosphatase and is frequently
deleted and mutated in various malignancies, including glioblasto-
mas, breast and prostate cancer (Steck et al, 1997; Li et al, 1997b;
Sano et al, 1999; Perren et al, 2000). Furthermore, previous
studies have reported frequent loss of heterozygosity at chromo-
some 10q23 in endometrial and thyroid cancers (Simpkins et al,
1998). This gene is considered to act as a tumour suppressor gene
in the pathogenesis of multiple cancers for several reasons: (i)
This gene is frequently mutated in tumours arising in patients
with Cowden disease and the Bannayan-Zonana syndrome, which
are both characterized as hereditary syndromes leading to multiple
hamartomas in the case of Cowden disease and both exhibit an
increased risk of developing breast, thyroid and skin cancer (Liaw
et al, 1997; Lynch et al, 1997; Marsh et al, 1997; Nelen et al,
1997). (ii) PTEN has been shown to act against phosphatidylino-
sitol phosphates, pointing to a role of PTEN as a mediator of the
phosphatidylinositol kinase pathway (Myers et al, 1997; Maehama
and Dixon, 1998). (iii) Expression of PTEN is associated with
growth inhibition and inhibition of transformation of epithelial
cells and PTEN exerts an inhibitory effect on the regulation of cell
spreading and migration. (iv) Furthermore, it has been shown to
induce apoptosis in vitro and in vivo (Stambolic et al, 1998;
Davies et al, 1999). In summary, the various biological aspects
of PTEN function support a role of PTEN as a tumour suppres-
sing gene in vivo and in vitro.
While we and others have identiﬁed a high frequency of growth
factor overexpression in pancreatic cancer, the molecular mechan-
isms of growth factor mediated pancreatic tumorigenesis remain
largely unknown (Korc et al, 1992; Ebert et al, 1995; Fujimoto et
al, 1998; Lo ¨hr et al, 2001). TGF-b1, the most prominent and well
characterized member of the large TGF-b superfamily, is highly
expressed in pancreatic cancers (Friess et al, 1993). Although it
exerts a growth inhibitory effect on pancreatic cancer cells in vitro,
its overexpression is associated with poor survival in patients with
advanced pancreatic cancer. In addition, the two other mammalian
isoforms of TGF-b, i.e. TGF-b2 and TGF-b3, are also overex-
pressed in pancreatic cancer (Friess et al, 1993; Satoh et al, 1998)
and human pancreatic cancers also express high levels of TGF-b
receptor II (TbR-II). In contrast, TbR-I is not aberrantly expressed
in pancreatic cancers (Korc, 1998).
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Figure 1 Immunohistochemical analysis of PTEN expression in pancreatic cancer. (A) In human pancreatic cancers PTEN immunoreactivity was present
in some of the cancer cells. (B) Sections incubated with the anti-PTEN antibody and the blocking peptide exhibited no PTEN immunoreactivity.
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to the growth inhibitory action of TGF-bs, however, is not fully
understood. TGF-b1 overexpression may result from the decreased
expression of its receptors (Korc, 1998). Furthermore, TbR-II
might be inactivated by mutation which has been reported in colon
and gastric cancers of the replication error positive phenotype. For
instance, in the MiaPaCa-2 pancreatic cancer cell line low levels of
TbR-II expression and mutation of the kinase domain have been
reported (Korc, 1998). In another study, mutations of the polyade-
nine tract of TbR-II and mutations in the kinase domain of the
TbR-II gene have been identiﬁed (Korc, 1998). In addition, the
inactivation of down-stream targets of TGF-b induced signalling
pathways, such as Smad4 which is mutated or deleted in a high
percentage of pancreatic cancers, may lead to a subsequent induc-
tion of TGF-b1 expression in pancreatic cancers (Hahn and
Schmiegel, 1998). Nonetheless, the overexpression of TGF-b1i n
pancreatic cancer has an important role in the pathogenesis of this
malignancy (Friess et al, 1993; Lo ¨hr et al, 2001). Through the
enhancement of tumour angiogenesis, the induction of the epithe-
lial-mesenchymal interaction, and the suppression of an adequate
immune response TGF-b1 may contribute to pancreatic tumour
development (Friess et al, 1993; Massague ￿, 1996; Lo ¨hr et al,
2001). Recently, several molecular alterations which are induced
by TGF-b1 in pancreatic cancer cells in vitro have been identiﬁed.
Thus, the induction of PDGFs and cyclin D1 in pancreatic cancer
cells by TGF-b1 has been reported (Ebert et al, 1995; Kornmann et
al, 1999). Our current study may further help to understand how
this growth factor may contribute to pancreatic cancer pathogen-
esis, despite its growth inhibitory effect on pancreatic cancer cells
in vitro. In this study we found signiﬁcantly decreased levels of
PTEN mRNA in pancreatic cancers. Since two reports have
demonstrated that PTEN mutations or deletions are not present
in pancreatic cancers (Sakurada et al, 1997; Okami et al, 1998),
other molecular mechanisms must contribute to its altered expres-
sion in pancreatic cancer. In a study by Li et al (1997a) the protein
tyrosine phosphatase PTEN was found to be rapidly down-regu-
lated by TGF-b1 in the HaCaT keratinocyte cell line. The
incubation of TGF-b1 at a concentration of 2 ng ml
71 to actively
growing HaCaT cells was associated with a marked reduction of
PTEN mRNA levels occurring within 2 h after addition of the cyto-
kine. While PTEN expression therefore seems to be regulated in
part by TGF-b1 (Li et al, 1997a), we raised the hypothesis that
the overexpression of TGF-b1 in pancreatic cancers may reduce
the expression of PTEN which in turn may give these cells an addi-
tional growth advantage. First, we determined the levels of PTEN
mRNA in human pancreatic cancers and found a signiﬁcant reduc-
tion of PTEN expression in pancreatic cancer cells. In order to
demonstrate that this reduction is mediated by TGF-b1, we
analyzed the expression of PTEN in a transgenic model of TGF-
b1 overexpressing mice. The pancreas of these transgenic mice
exhibits massive ﬁbrosis (Sanvito et al, 1995). Our analysis revealed
a reduction of PTEN mRNA levels in the pancreas of these mice as
compared to wildtype littermates. To further substantiate our ﬁnd-
ings, we incubated PANC-1 pancreatic cancer cells with TGF-b1
and found a dramatic reduction of PTEN mRNA levels in these
cells. Interestingly, the reduction of PTEN mRNA levels in the
PANC-1 cell line was present after 24 h incubation with TGF-b1
in contrast to the report by Li et al (1997a) who found a rapid
decline of PTEN mRNA levels within 2 h after addition of TGF-
b1. While we only analyzed the PTEN mRNA levels 12 and 24 h
after incubation of PANC-1 cells with TGF-b1, we cannot exclude
the possibility that a rapid reduction of PTEN mRNA levels had
taken place earlier in the pancreatic cancer cells as well, which
may have been followed by a restitution of PTEN mRNA levels
and a second decrease 24 h after treatment of the cells. Further-
more, the concentrations of TGF-b1 in our study and that by Li
et al (1997a) were different, so that a dose-dependent effect may
also play a role in these ﬁndings. Nonetheless our studies conﬁrm
that PTEN mRNA levels are regulated and controlled at least in
part by TGF-b1, which supports our hypothesis that the overex-
pression of TGF-b1 in pancreatic cancer may contribute to
reduced PTEN mRNA levels in this malignancy. Thus, in conclu-
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Figure 2 RT–PCR analysis of PTEN mRNA levels in a pancreatic cancer
cell line, in human and murine pancreas. (A) Semiquantitative analysis re-
vealed decreased expression of PTEN mRNA in pancreatic cancers (right)
as compared to the normal pancreas (left). Last lane, DNA ladder. (B)I n
transgenic mice overexpressing TGF-b1 (TGF-b1 tg) PTEN mRNA levels
were also decreased as compared to wildtype littermates (wildtype). Last
lane, DNA ladder. (C) Densitometric analysis conﬁrmed a signiﬁcant reduc-
tion of PTEN mRNA levels in pancreatic tumours (T) as compared to the
normal pancreas (N) and in TGF-b1 transgenic mice (Tg) as compared to
wildtype mice (Wt). Mean +s.d.; &, PTEN mRNA levels as determined by
densitometric analysis and standardization against their respective enolase
mRNA or GAP mRNA levels; $, P50.05. (D) Incubation of PANC-1 cells
with TGF-b1 led to a signiﬁcant reduction of PTEN mRNA levels after
24 h, however not after 12 h. +, addition of TGF-b1; 7, control without
agonist addition; M, DNA ladder.
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expression of this tumour suppressor in pancreatic cancers may
result from the overexpression of TGF-b1.
Besides the regulation by TGF-b1, other molecular mechanisms
may also contribute to the downregulation of PTEN expression in
malignant tumours. Thus, the reduced expression of PTEN may
result from hypermethylation of the PTEN promotor, the enhanced
degradation of the transcript or the transcriptional inactivation of
the gene (Lynch et al, 1997; Whang et al, 1998). For instance, in
Cowden disease, nonsense-mediated degradation of the gene was
reported (Liaw et al, 1997; Lynch et al, 1997; Nelen et al, 1997).
In addition, in a study using prostate cancer tissues and cell lines,
the treatment of the cells with the demethylating agent 5-azadeox-
ycytidine led to the restoration of PTEN mRNA levels, which
reﬂects a possible role of hypermethylation of the promotor in
the regulation of PTEN transcription (Whang et al, 1998). We
did not study the methylation status of the PTEN promotor in
our cancer samples. In fact, our study indicates that TGF-b1
contributes to reduced PTEN mRNA levels in pancreatic cancers.
Thus, despite the fact that PTEN inactivation through PTEN
mutation or deletion is infrequent in pancreatic cancer, we raise
the hypothesis that TGF-b1 overexpression may lead to reduced
PTEN mRNA levels in pancreatic cancers which may give these
cells an additional growth advantage and, thus, contributes to the
aggressive phenotype of this cancer.
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